Skip to main content
Article thumbnail
Location of Repository

AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity

By Donna A. MacDuff, Zachary L. Demorest and Reuben S. Harris

Abstract

Retrotransposons make up over 40% of the mammalian genome. Some copies are still capable of mobilizing and new insertions promote genetic variation. Several members of the APOBEC3 family of DNA cytosine deaminases function to limit the replication of a variety of retroelements, such as the long-terminal repeat (LTR)-containing MusD and Ty1 elements, and that of the non-LTR retrotransposons, L1 and Alu. However, the APOBEC3 genes are limited to mammalian lineages, whereas retrotransposons are far more widespread. This raises the question of what cellular factors control retroelement transposition in species that lack APOBEC3 genes. A strong phylogenetic case can be made that an ancestral activation-induced deaminase (AID)-like gene duplicated and diverged to root the APOBEC3 lineage in mammals. Therefore, we tested the hypothesis that present-day AID proteins possess anti-retroelement activity. We found that AID can inhibit the retrotransposition of L1 through a DNA deamination-independent mechanism. This mechanism may manifest in the cytoplasmic compartment co- or posttranslationally. Together with evidence for AID expression in the ovary, our data combined to suggest that AID has innate immune functions in addition to its integral roles in creating antibody diversity

Topics: Molecular Biology
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:2665220
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2002). A mouse model of human L1 retrotransposition.
    2. (1995). A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks.
    3. (2001). A novel active L1 retrotransposon subfamily in the mouse.
    4. (2006). A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus.
    5. (2000). Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).
    6. (2006). Activation-induced cytidine deaminase (AID) is expressed in normal spermatogenesis but only infrequently in testicular germ cell tumours.
    7. (2004). Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming.
    8. (2003). Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase.
    9. (2004). Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1.
    10. (2005). AID from bony fish catalyzes class switch recombination.
    11. (2002). AID is essential for immunoglobulin V gene conversion in a cultured B cell line.
    12. (2003). AID mediates hypermutation by deaminating single stranded DNA.
    13. (2003). AID mutant analyses indicate requirement for class-switch-specific cofactors.
    14. (2002). AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification.
    15. (2002). AID-GFP chimeric protein increases hypermutation of Ig genes with no evidence of nuclear localization.
    16. (2007). All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition.
    17. (2004). An active murine transposon family pair: retrotransposition of ‘‘master’’ MusD copies and ETn trans-mobilization.
    18. (2004). Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
    19. (2008). Antiretroelement activity of APOBEC3H was lost twice in recent human evolution.
    20. (2006). APOBEC3 proteins inhibit human LINE-1 retrotransposition.
    21. (2006). APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.
    22. (2006). APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    23. (2004). APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
    24. (2006). APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deaminationindependent mechanism.
    25. (2007). APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation.
    26. (2008). APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.
    27. (2005). APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.
    28. (2005). APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.
    29. (2007). Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
    30. (2005). Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    31. (2006). Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
    32. (2000). Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.
    33. (2004). Cloning and expression of the AID gene in the channel catfish.
    34. (2007). Clustal W and Clustal X version
    35. (2008). Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences.
    36. (2000). Determination of L1 retrotransposition kinetics in cultured cells.
    37. (2007). Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecularmass-complex formation or P-body association.
    38. (2006). Directed DNA deamination by AID/APOBEC3 in immunity.
    39. (2007). DNA deamination in immunity: AID in the context of its APOBEC relatives.
    40. (2003). DNA deamination mediates innate immunity to retroviral infection.
    41. (2006). Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses.
    42. (2006). Endogenous factors enhance HIV infection of tissue naive CD4T cells by stimulating high molecular mass APOBEC3G complex formation.
    43. (2007). Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
    44. (2008). Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.
    45. (2002). Evidence consistent with human L1 retrotransposition in maternal meiosis I.
    46. (2005). Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases.
    47. (2007). Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis.
    48. (2007). Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling.
    49. (2007). Fahrenkrug,S.C., Andre ´ sdo ´ ttir,V. and Harris,R.S.
    50. (2006). GARD: a genetic algorithm for recombination detection.
    51. (2007). Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium.
    52. (2006). Highmolecular-mass APOBEC3G complexes restrict Alu retrotransposition.
    53. (2008). HIV-1 accessory proteins– ensuring viral survival in a hostile environment.
    54. (2003). Hot L1s account for the bulk of retrotransposition in the human population.
    55. (2002). Human L1 element target-primed reverse transcription in vitro.
    56. (2008). Hypermutation of an ancient human retrovirus by APOBEC3G.
    57. (1991). Increased ratio of targeted to random integration after transfection of chicken B cell lines.
    58. (2005). Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
    59. (2001). Initial sequencing and analysis of the human genome.
    60. (2008). Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1.
    61. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    62. (1996). Membrane exon sequences of the three Xenopus Ig classes explain the evolutionary origin of mammalian isotypes.
    63. (2000). Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome.
    64. (2006). PAL2NAL: robust conversion of protein sequence alignments into the corresponding codon alignments.
    65. (2004). PEDE (Pig EST Data Explorer): construction of a database for ESTs derived from porcine full-length cDNA libraries.
    66. (2000). Phylogenetic analysis using PHYLIP.
    67. (2006). PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells.
    68. (1998). Rapid amplification of a retrotransposon subfamily is evolving the mouse genome.
    69. (2004). Rapid evolution of primate antiviral enzyme APOBEC3G.
    70. (2004). Recombinogenic phenotype of human activation-induced cytosine deaminase.
    71. (2008). Regulation of class switch recombination and somatic mutation by AID phosphorylation.
    72. (2006). Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation.
    73. (2002). Requirement of the activation-induced deaminase (AID) gene for immunoglobulin gene conversion.
    74. (2008). Restriction by APOBEC3 proteins of endogenous retroviruses with an extracellular life cycle: ex vivo effects and in vivo ‘‘traces’’ on the murine IAPE and human HERV-K elements.
    75. (2006). Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line.
    76. (2004). Retroviral restriction by APOBEC proteins.
    77. (1993). Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition.
    78. (2002). RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.
    79. (2007). Role of activation-induced deaminase protein kinase A phosphorylation sites in Ig gene conversion and somatic hypermutation.
    80. (2007). Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses.
    81. (2007). Selective inhibition of Alu retrotransposition by APOBEC3G.
    82. (2004). Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase.
    83. (1993). Somatic variation precedes extensive diversification of germline sequences and combinatorial joining in the evolution 1864
    84. (2006). Structural phylogenetic analysis of activation-induced deaminase function.
    85. (2005). The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation.
    86. (2008). The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
    87. (2008). The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals.
    88. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    89. (2008). The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodefi-ciency virus type 1 restriction.
    90. (2004). The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay.
    91. (2004). The Jalview Java alignment editor.
    92. (2004). The phylogenetic origins of the antigen-binding receptors and somatic diversification mechanisms.
    93. (2003). Tracking an embryonic L1 retrotransposition event.
    94. (2003). Transcription-targeted DNA deamination by the AID antibody diversification enzyme.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.